Iceland· IS-EU/1/20/1452/002
Reblozyl
A luspatercept product containing luspaterceptum inn, registered in Iceland by Bristol-Myers Squibb Pharma EEIG*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Luspatercept is registered in 14 of 19 countries.
Countries holding a registration under ATC B03XA06 (luspatercept), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 10 of them publish a price we can compare per daily dose
Luspatercept · ATC B03XA06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Luspaterceptum INN
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG*
- Country
- Iceland (IS)
- ATC code
- B03XA06
- ATC class
- Luspatercept
- Defined daily dose
- 3.33 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Luspatercept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumReblozyl 75 mgBristol-Myers Squibb Pharma
- SwitzerlandReblozyl 75 mg, Pulver zur Herstellung einer InjektionslösungBristol-Myers Squibb SA
- CzechiaREBLOZYLBristol-Myers Squibb Pharma EEIG, Dublin
- SpainREBLOZYL 75 MG POLVO PARA SOLUCION INYECTABLEBristol-Myers Squibb Pharma Eeig
- NorwayReblozylBristol-Myers Squibb Pharma EEIG (1)
- PolandReblozylBristol-Myers Squibb Pharma EEIG
- SwedenReblozyl 75 mg Pulver till injektionsvätska, lösningBristol-Myers Squibb Pharma EEIG
- CanadaREBLOZYLBRISTOL-MYERS SQUIBB CANADA
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Reblozyl
- Norway · Reblozyl
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9d69d59c-7e19-4318-936c-ebffa61618a3 GET /v1/drugs/9d69d59c-7e19-4318-936c-ebffa61618a3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyfsstofn, lausn",
"source": "lyfjastofnun",
"atc_raw": "B03XA06",
"marketed": false,
"strength": "75 mg",
"ma_number": "EU/1/20/1452/002",
"substance": "Luspaterceptum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum og krabbameinslækningum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "44007"
}See everything about luspatercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.